Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor

MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume

Lupin to present Phase 1 Data on LNP7457 at ASCO Annual Meeting 2025

Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr

For the full year FY25, net profit soared 12x to Rs 345 crore

Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants

Tata 1mg optimises e-commerce operations with Unicommerce

Sun Pharma gets FDA approval for new device to treat skin disease

Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India